No association between migraine and breast cancer risk
the ONA take:
According to a new study published in the Journal of the National Cancer Institute, researchers at Harvard University Medical School in Boston, Massachusetts, have found that there is no associated between migraines and risk of breast cancer.
For the studies, researchers analyzed four other studies that included over 100,000 women actually found that migraines may decrease the risk of breast cancer, but researchers note that this finding may be due to study design rather than a real association.
The theory that there was a link between migraines and risk of breast cancer comes up from the notion that both arise from increased sex hormone levels. When the research team analyzed the levels of sex hormones in about 2,000 premenopausal women who experience migraines, the researchers found no link between the two.
According to the Migraine Research Foundation, approximately 18% of American women and 6% of American men experience migraines. A migraine is a severe headache that is often accompanied by sensitivity to light and sound, nausea, visual disturbances, and vomiting. A migraine can last anywhere between 4 hour and 3 days.
There is no associated between migraines and risk of breast cancer.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|